Inhibrx Biosciences IncNASDAQ:INBX
- LAST PRICE14.7600
- TODAY'S CHANGE (%)-0.1200 (-0.8065%)
- Bid / Lots5.9100/ 2
- Ask / Lots16.5500/ 1
- Open / Previous Close15.0600 / 14.8800
- Day Range
- 52 Week Range
- Volume53,308
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | INBX |
|---|---|---|
| 09:32 ET | 1440 | 14.8101 |
| 09:57 ET | 100 | 14.89 |
| 10:03 ET | 100 | 14.9 |
| 11:02 ET | 100 | 15.01 |
| 11:11 ET | 1000 | 15.0109 |
| 11:42 ET | 100 | 14.91 |
| 01:03 ET | 614 | 14.985 |
| 01:17 ET | 400 | 14.93 |
| 01:30 ET | 400 | 14.91 |
| 01:35 ET | 300 | 14.82 |
| 01:44 ET | 300 | 14.815 |
| 01:53 ET | 200 | 14.76 |
| 02:00 ET | 100 | 14.79 |
| 02:09 ET | 100 | 14.78 |
| 02:26 ET | 100 | 14.79 |
| 02:29 ET | 200 | 14.75 |
| 02:44 ET | 652 | 14.78 |
| 02:45 ET | 200 | 14.78 |
| 02:58 ET | 300 | 14.82 |
| 03:02 ET | 100 | 14.78 |
| 03:14 ET | 100 | 14.7625 |
| 03:23 ET | 145 | 14.78 |
| 03:27 ET | 185 | 14.7685 |
| 03:32 ET | 636 | 14.815 |
| 03:34 ET | 1202 | 14.8 |
| 03:36 ET | 100 | 14.79 |
| 03:38 ET | 1885 | 14.77 |
| 03:39 ET | 600 | 14.77 |
| 03:41 ET | 2000 | 14.745 |
| 03:43 ET | 100 | 14.76 |
| 03:45 ET | 700 | 14.77 |
| 03:48 ET | 1300 | 14.76 |
| 03:50 ET | 700 | 14.79 |
| 03:52 ET | 706 | 14.76 |
| 03:54 ET | 3014 | 14.72 |
| 03:56 ET | 2000 | 14.74 |
| 03:57 ET | 2642 | 14.74 |
| 03:59 ET | 12486 | 14.76 |
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Inhibrx Biosciences Inc | 215.4M | 0.1x | --- |
Candel Therapeutics Inc | 215.3M | -3.9x | --- |
XBiotech Inc | 214.8M | -6.5x | --- |
Immutep Ltd | 310.4M | -8.5x | --- |
Acrivon Therapeutics Inc | 213.4M | -2.5x | --- |
Trevi Therapeutics Inc | 219.2M | -7.8x | --- |
Company Information
Inhibrx Biosciences, Inc. is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. The Company’s clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106. INBRX-109 is a tetravalent agonist of death receptor 5 (DR5) that is designed with its proprietary single domain antibody, or sdAb, platform to drive cancer-selective programmed cell death and to maximize potency while minimizing on-target liver toxicity arising from hepatocyte apoptosis. INBRX-106 is a hexavalent OX40 agonist, being investigated as a single agent and in combination with Keytruda, a PD-1 blocking checkpoint inhibitor, in patients with locally advanced or metastatic solid tumors. INBRX-106 is a precisely engineered hexavalent sdAb-based therapeutic candidate targeting OX40, designed to be an optimized agonist of this co-stimulatory receptor.
Contact Information
- Headquarters
- 11025 N. Torrey Pines Road, Suite 140LA JOLLA, CA, United States 92037
- Phone
- 858-795-4220
- Fax
- 302-636-5454
Executives
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $215.4M |
|---|---|
Revenue (TTM) | $1.9M |
Shares Outstanding | 14.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $121.21 |
Book Value | $0.92 |
P/E Ratio | 0.1x |
Price/Sales (TTM) | 116.2 |
Price/Cash Flow (TTM) | 0.1x |
Operating Margin | 89,188.29% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
